Prazer Therapeutics

2:30 PM - 2:45 PM (EDT), Monday, June 5, 2023 ・ Session Room 104A
Prazer Therapeutics is a Korean biotech company pioneering innovative small molecule therapeutics with a novel approach in targeted protein degradation (TPD). Prazer strives to overcome the limitations of first-generation TPD therapeutics with a proprietary TPD platform named SPiDEM (Selective Protein Degradation Enabling Moiety).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
Korea, Republic of
Year Founded:
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
SPiDEM degraders targeting Tau and α-Synuclein
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
• Two (for strategic collaboration of in-house programs: SPiDEM degraders targeting Tau and α-Synuclein) • Unlimited (for strategic collaboration to identify and develop novel targeted protein degraders by leveraging Prazer’s SPiDEM platform
Transforming the Future of Targeted Protein Degradation (TPD) with SPiDEM
Prazer Therapeutics